Cargando…

Plasma-only circulating tumor DNA analysis detects minimal residual disease and predicts early relapse in hepatocellular carcinoma patients undergoing curative resection

BACKGROUND: Minimal residual disease (MRD) is considered an essential factor leading to relapse within 2 years (early relapse) after radical surgery, which is challenging to be detected by conventional imaging. Circulating tumor DNA (ctDNA) provides a novel approach for detecting MRD and predicting...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Yuyan, Cai, Jianpeng, Zhong, Kaihang, Wen, Yaohong, Cai, Lei, He, Guolin, Liao, Hangyu, Zhang, Cheng, Fu, Shunjun, Chen, Tingting, Cai, Jinping, Zhong, Xuefeng, Chen, Chunzhu, Huang, Mengli, Cheng, Yuan, Pan, Mingxin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028131/
https://www.ncbi.nlm.nih.gov/pubmed/36959801
http://dx.doi.org/10.3389/fonc.2023.1119744
_version_ 1784909875799654400
author Xu, Yuyan
Cai, Jianpeng
Zhong, Kaihang
Wen, Yaohong
Cai, Lei
He, Guolin
Liao, Hangyu
Zhang, Cheng
Fu, Shunjun
Chen, Tingting
Cai, Jinping
Zhong, Xuefeng
Chen, Chunzhu
Huang, Mengli
Cheng, Yuan
Pan, Mingxin
author_facet Xu, Yuyan
Cai, Jianpeng
Zhong, Kaihang
Wen, Yaohong
Cai, Lei
He, Guolin
Liao, Hangyu
Zhang, Cheng
Fu, Shunjun
Chen, Tingting
Cai, Jinping
Zhong, Xuefeng
Chen, Chunzhu
Huang, Mengli
Cheng, Yuan
Pan, Mingxin
author_sort Xu, Yuyan
collection PubMed
description BACKGROUND: Minimal residual disease (MRD) is considered an essential factor leading to relapse within 2 years (early relapse) after radical surgery, which is challenging to be detected by conventional imaging. Circulating tumor DNA (ctDNA) provides a novel approach for detecting MRD and predicting clinical outcomes. Here, we tried to construct a fixed panel for plasma-only ctDNA NGS to enable tumor-uninformed MRD detection in hepatocellular carcinoma (HCC). METHODS: Here, we performed the followings: (i) profiling genomic alteration spectrum of ctDNA from the Chinese HCC cohort consisting of 493 individuals by NGS; (ii) screening of MRD monitoring genes; and (iii) performance evaluation of MRD monitoring genes in predicting early relapse in the ZJZS2020 cohort comprising 20 HCC patients who underwent curative resection. RESULTS: A total of 493 plasma samples from the Chinese HCC cohort were detected using a 381/733-gene NGS panel to characterize the mutational spectrum of ctDNA. Most patients (94.1%, 464/493) had at least one mutation in ctDNA. The variants fell most frequently in TP53 (45.1%), LRP1B (20.2%), TERT (20.2%), FAT1 (16.2%), and CTNNB1 (13.4%). By customized filtering strategy, 13 MRD monitoring genes were identified, and any plasma sample with one or more MRD monitoring gene mutations was considered MRD-positive. In the ZJZS2020 cohort, MRD positivity presented a sensitivity of 75% (6/8) and a specificity of 100% (6/6) in identifying early postoperative relapse. The Kaplan-Meier analysis revealed a significantly short relapse-free survival (RFS; median RFS, 4.2 months vs. NR, P=0.002) in the MRD-positive patients versus those with MRD negativity. Cox regression analyses revealed MRD positivity as an independent predictor of poor RFS (HR 13.00, 95% CI 2.60-69.00, P=0.002). CONCLUSIONS: We successfully developed a 13-gene panel for plasma-only MRD detection, which was effective and convenient for predicting the risk of early postoperative relapse in HCC.
format Online
Article
Text
id pubmed-10028131
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100281312023-03-22 Plasma-only circulating tumor DNA analysis detects minimal residual disease and predicts early relapse in hepatocellular carcinoma patients undergoing curative resection Xu, Yuyan Cai, Jianpeng Zhong, Kaihang Wen, Yaohong Cai, Lei He, Guolin Liao, Hangyu Zhang, Cheng Fu, Shunjun Chen, Tingting Cai, Jinping Zhong, Xuefeng Chen, Chunzhu Huang, Mengli Cheng, Yuan Pan, Mingxin Front Oncol Oncology BACKGROUND: Minimal residual disease (MRD) is considered an essential factor leading to relapse within 2 years (early relapse) after radical surgery, which is challenging to be detected by conventional imaging. Circulating tumor DNA (ctDNA) provides a novel approach for detecting MRD and predicting clinical outcomes. Here, we tried to construct a fixed panel for plasma-only ctDNA NGS to enable tumor-uninformed MRD detection in hepatocellular carcinoma (HCC). METHODS: Here, we performed the followings: (i) profiling genomic alteration spectrum of ctDNA from the Chinese HCC cohort consisting of 493 individuals by NGS; (ii) screening of MRD monitoring genes; and (iii) performance evaluation of MRD monitoring genes in predicting early relapse in the ZJZS2020 cohort comprising 20 HCC patients who underwent curative resection. RESULTS: A total of 493 plasma samples from the Chinese HCC cohort were detected using a 381/733-gene NGS panel to characterize the mutational spectrum of ctDNA. Most patients (94.1%, 464/493) had at least one mutation in ctDNA. The variants fell most frequently in TP53 (45.1%), LRP1B (20.2%), TERT (20.2%), FAT1 (16.2%), and CTNNB1 (13.4%). By customized filtering strategy, 13 MRD monitoring genes were identified, and any plasma sample with one or more MRD monitoring gene mutations was considered MRD-positive. In the ZJZS2020 cohort, MRD positivity presented a sensitivity of 75% (6/8) and a specificity of 100% (6/6) in identifying early postoperative relapse. The Kaplan-Meier analysis revealed a significantly short relapse-free survival (RFS; median RFS, 4.2 months vs. NR, P=0.002) in the MRD-positive patients versus those with MRD negativity. Cox regression analyses revealed MRD positivity as an independent predictor of poor RFS (HR 13.00, 95% CI 2.60-69.00, P=0.002). CONCLUSIONS: We successfully developed a 13-gene panel for plasma-only MRD detection, which was effective and convenient for predicting the risk of early postoperative relapse in HCC. Frontiers Media S.A. 2023-03-07 /pmc/articles/PMC10028131/ /pubmed/36959801 http://dx.doi.org/10.3389/fonc.2023.1119744 Text en Copyright © 2023 Xu, Cai, Zhong, Wen, Cai, He, Liao, Zhang, Fu, Chen, Cai, Zhong, Chen, Huang, Cheng and Pan https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Xu, Yuyan
Cai, Jianpeng
Zhong, Kaihang
Wen, Yaohong
Cai, Lei
He, Guolin
Liao, Hangyu
Zhang, Cheng
Fu, Shunjun
Chen, Tingting
Cai, Jinping
Zhong, Xuefeng
Chen, Chunzhu
Huang, Mengli
Cheng, Yuan
Pan, Mingxin
Plasma-only circulating tumor DNA analysis detects minimal residual disease and predicts early relapse in hepatocellular carcinoma patients undergoing curative resection
title Plasma-only circulating tumor DNA analysis detects minimal residual disease and predicts early relapse in hepatocellular carcinoma patients undergoing curative resection
title_full Plasma-only circulating tumor DNA analysis detects minimal residual disease and predicts early relapse in hepatocellular carcinoma patients undergoing curative resection
title_fullStr Plasma-only circulating tumor DNA analysis detects minimal residual disease and predicts early relapse in hepatocellular carcinoma patients undergoing curative resection
title_full_unstemmed Plasma-only circulating tumor DNA analysis detects minimal residual disease and predicts early relapse in hepatocellular carcinoma patients undergoing curative resection
title_short Plasma-only circulating tumor DNA analysis detects minimal residual disease and predicts early relapse in hepatocellular carcinoma patients undergoing curative resection
title_sort plasma-only circulating tumor dna analysis detects minimal residual disease and predicts early relapse in hepatocellular carcinoma patients undergoing curative resection
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028131/
https://www.ncbi.nlm.nih.gov/pubmed/36959801
http://dx.doi.org/10.3389/fonc.2023.1119744
work_keys_str_mv AT xuyuyan plasmaonlycirculatingtumordnaanalysisdetectsminimalresidualdiseaseandpredictsearlyrelapseinhepatocellularcarcinomapatientsundergoingcurativeresection
AT caijianpeng plasmaonlycirculatingtumordnaanalysisdetectsminimalresidualdiseaseandpredictsearlyrelapseinhepatocellularcarcinomapatientsundergoingcurativeresection
AT zhongkaihang plasmaonlycirculatingtumordnaanalysisdetectsminimalresidualdiseaseandpredictsearlyrelapseinhepatocellularcarcinomapatientsundergoingcurativeresection
AT wenyaohong plasmaonlycirculatingtumordnaanalysisdetectsminimalresidualdiseaseandpredictsearlyrelapseinhepatocellularcarcinomapatientsundergoingcurativeresection
AT cailei plasmaonlycirculatingtumordnaanalysisdetectsminimalresidualdiseaseandpredictsearlyrelapseinhepatocellularcarcinomapatientsundergoingcurativeresection
AT heguolin plasmaonlycirculatingtumordnaanalysisdetectsminimalresidualdiseaseandpredictsearlyrelapseinhepatocellularcarcinomapatientsundergoingcurativeresection
AT liaohangyu plasmaonlycirculatingtumordnaanalysisdetectsminimalresidualdiseaseandpredictsearlyrelapseinhepatocellularcarcinomapatientsundergoingcurativeresection
AT zhangcheng plasmaonlycirculatingtumordnaanalysisdetectsminimalresidualdiseaseandpredictsearlyrelapseinhepatocellularcarcinomapatientsundergoingcurativeresection
AT fushunjun plasmaonlycirculatingtumordnaanalysisdetectsminimalresidualdiseaseandpredictsearlyrelapseinhepatocellularcarcinomapatientsundergoingcurativeresection
AT chentingting plasmaonlycirculatingtumordnaanalysisdetectsminimalresidualdiseaseandpredictsearlyrelapseinhepatocellularcarcinomapatientsundergoingcurativeresection
AT caijinping plasmaonlycirculatingtumordnaanalysisdetectsminimalresidualdiseaseandpredictsearlyrelapseinhepatocellularcarcinomapatientsundergoingcurativeresection
AT zhongxuefeng plasmaonlycirculatingtumordnaanalysisdetectsminimalresidualdiseaseandpredictsearlyrelapseinhepatocellularcarcinomapatientsundergoingcurativeresection
AT chenchunzhu plasmaonlycirculatingtumordnaanalysisdetectsminimalresidualdiseaseandpredictsearlyrelapseinhepatocellularcarcinomapatientsundergoingcurativeresection
AT huangmengli plasmaonlycirculatingtumordnaanalysisdetectsminimalresidualdiseaseandpredictsearlyrelapseinhepatocellularcarcinomapatientsundergoingcurativeresection
AT chengyuan plasmaonlycirculatingtumordnaanalysisdetectsminimalresidualdiseaseandpredictsearlyrelapseinhepatocellularcarcinomapatientsundergoingcurativeresection
AT panmingxin plasmaonlycirculatingtumordnaanalysisdetectsminimalresidualdiseaseandpredictsearlyrelapseinhepatocellularcarcinomapatientsundergoingcurativeresection